Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study
Flibanserin (FLB) was approved by FDA for the treatment of pre-menopausal female hypoactive sexual desire disorder (HSDD). FLB suffers from low oral bioavailability (33%) which might be due to hepatic first-pass metabolism in addition to its poor aqueous solubility. The sublingual route could be a p...
में बचाया:
मुख्य लेखकों: | , |
---|---|
स्वरूप: | पुस्तक |
प्रकाशित: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
विषय: | |
ऑनलाइन पहुंच: | Connect to this object online. |
टैग: |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|
इंटरनेट
Connect to this object online.3rd Floor Main Library
बोधानक: |
A1234.567 |
---|---|
प्रति 1 | उपलब्ध |